Research programme: Tau protein modulators - Abbvie/BioMed X

Drug Profile

Research programme: Tau protein modulators - Abbvie/BioMed X

Latest Information Update: 06 Jun 2015

Price : $50

At a glance

  • Originator AbbVie; BioMed X
  • Class
  • Mechanism of Action Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 30 Mar 2015 Early research in Alzheimer's disease in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top